http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114177293-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a8fdc4ccb0459c073d9568cdee35dea |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2021-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b2adc5d449eea55de01369679f51ad5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d784c620b989135ac33d48edfc033a20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a964b1b31dc60e28d66dfd510ef5adc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01c2026d627dffe7130c81c96fba94c4 |
| publicationDate | 2022-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114177293-A |
| titleOfInvention | Application of a kind of targeting miR-493/HIF-1α/PDK1 to prepare drug-resistant drugs |
| abstract | The invention discloses an application of targeting miR-493/HIF-1α/PDK1 to prepare drug-resistant drugs, and the application of miR-493, HIF-1α and PDK1 in the preparation of drugs for treating lung cancer caused by chromium exposure, including miR-493, HIF-1α and PDK1. Application of -493, HIF-1α and PDK1 in the preparation of a drug for treating lung cancer caused by chromium exposure, the drug for treating lung cancer caused by chromium exposure comprising a drug, a carrier and an adjuvant targeting miR-493, HIF-1α and PDK1, The drug for reversing tumor multidrug resistance can be prepared in the form of tablets, granules, capsules or solutions, and the tumor drug resistance detection includes targeting miR-493, HIF-1α and PDK1 or downstream main regulatory molecules As a detection reagent or detection kit for a target, the present invention conducts experiments at multiple levels such as function, cell, protein, etc. through in vitro and in vivo experiments to prove that targeting miR-493, HIF-1α and PDK1 mediate chromium exposure. Development of lung cancer. |
| priorityDate | 2021-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.